Nicox SA ALCOX
EURONEXT · France · Health Technology
€0.3250-0.01 (-2.69%)
Market closed· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Press Release Data on Nicox's NCX 470 to be presented at AAOpt Annual Meeting 2026September 16, 2026 – release at 7:30 amSophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that key scientific data on NCX 470 will be presented at the upcoming American Academy of Optometry (AAOpt) Annual Meeting 2026 (September 30 – October 3, 2026, Anaheim, CA, U.S.). Nicox will also be participating in several key ophthalmology,
Press Release Nicox Announces Extension of Cash Runway Cash position, of €8.4 million1 as of 31 August 2026, sufficient to fund existing operations beyond Q1 2028NCX 470 U.S. NDA approval milestone would fund operations into 2029, while subsequent royalties could extend the cash runway substantially further Discussions on future strategic opportunities continuing September 2, 2026 – release at 7:30 am CETSophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an internatio
Press Release Nicox Announces April 2027 PDUFA Date for NCX 470 in Glaucoma FDA sets Prescription Drug User Fee Act (PDUFA) review response date by 30 April 2027Two NDAs filed in major markets, with commercial partners in place for expected launches from H2 2027 onwardsMilestone payment due on U.S. NDA approval plus royalties on salesNCX 470 Phase 3 program ongoing in Japan in support of approvalQ&A available on Nicox’s website August 27, 2026 – release at 7:30 am CETSophia Antipolis, FranceNico
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.